Sentences with phrase «myeloma drug»

The screening method suggests which commonly prescribed multiple myeloma drug, or combination of drugs, a physician should consider first for a particular patient.

That includes Revlimid, a multiple myeloma drug with annual sales that hit $ 8.2 billion last year.

Johnson & Johnson also has a fast - growing multiple myeloma drug with Darzalex.

Multiple myeloma drug Revlimid and anti-inflammatory Otezla have the potential to grow sales by double - digits throughout the remainder of the decade while also expanding into a number of new indications.

Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late - stage study.

Shares of Ligand Pharmaceuticals shed nearly 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late - stage study.

Celgene loses patent protection by 2022 for Revlimid, its top - selling multiple myeloma drug that brought in about 60 percent of fiscal third quarter revenue of nearly $ 3.3 billion.

So far, its trials have shown it can improve outcomes when used alongside other multiple myeloma drugs and that could offer it some insulation if the market gets disrupted by new treatment approaches, such as gene therapy.

The FDA approved Kyprolis for patients who have already been treated with at least two other multiple myeloma drugs, and Onyx is conducting other trials to win broader marketing approval.

Not exact matches

When Kathy Giusti founded the Multiple Myeloma Research Foundation, there were no drugs for the blood cancer.

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaDrug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deadrug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

Within weeks of her diagnosis in 1996, Giusti began disrupting the myeloma research culture — getting isolated doctors and scientists to share data, and building an unheard - of consortium to develop drugs.

Empliciti will be used in combination with two other drugs to treat patients with multiple myeloma who have received one to three prior courses of medication.

Earlier this month, the FDA approved two other treatments for multiple myeloma, including another kind of monoclonal antibody drug (the same class of drug that elotuzumab is in).

Celgene (CELG) sells Revlimid to treat myeloma and Amgen is in the process of getting into the field with the acquisition of Onyx and its Kyprolis drug, also for the treatment of myeloma.

Celgene's lead product, Revlimid, a drug designed to treat multiple myeloma and a few other cancer types, has been benefiting from longer duration of use, strong pricing power, and high multiple myeloma market share.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.

With multiple myeloma, most patients live four to seven years from their date of diagnosis, and most become resistant to chemotherapy drugs over time.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

Of 32 patients participating in the trial, 11 had a partial response to the drug regimen, meaning a decrease in the extent of the cancer, and 53 had a very good partial response, meaning the level of certain myeloma - related proteins in the blood declines by more than 90 percent.

The idea is to use the understanding of the pathways that adiponectin uses to kill myeloma cells to create a drug that would do the same thing.

The nanoparticles carry a drug compound that blocks a protein called Myc that is active in many types of cancer, including multiple myeloma.

«Today, we have half a dozen drugs for multiple myeloma that can put patients into remission,» said Tomasson, who treats patients with multiple myeloma at Siteman Cancer Center at Barnes - Jewish Hospital and Washington University School of Medicine.

NMP shares certain mechanistic similarities with other promising drug candidates for myeloma that were discovered in more traditional ways.

The U.S. Food and Drug Administration approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therDrug Administration approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therdrug on Nov. 20 for patients with myeloma who have received at least one previous therapy.

«Immunotherapy agent benefits patients with drug - resistant multiple myeloma.»

Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple - myeloma patients.

The company in - licensed thalidomide in 1992 and received FDA approval to market the drug (as Thalomid) for treating severe cutaneous manifestations of leprosy in 1998 and for treating multiple myeloma in combination with dexamethasone in 2006.

«Personalized drug screening on horizon for multiple myeloma patients.»

The findings are particularly noteworthy because drugs that act on the newly discovered target, a protein known as PIM1, are already in clinical trials for leukemia and multiple myeloma.

Doctors have many drugs available to treat multiple myeloma, a type of blood cancer.

The finding that LCL161 is active against multiple myeloma suggests that similar drugs may have broader clinical activity than previously thought.

A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.

In examining these remaining myeloma cells, the Yale team discovered a previously unidentified biologic pathway induced by the immune modulating drugs that enabled the residual cancer cells to survive and proliferate.

«Preventing the degradation of MBD3 protein will make it difficult for myeloma cells to escape this class of drugs,» said senior author Madhav Dhodapkar, professor of immunobiology and chief of the Section of Hematology.

Initial treatment for most multiple myeloma patients includes a class of drugs (Revlimid or Pomalyst) broadly known as immune modulators.

In the 1990s the U.S. Food and Drug Administration approved its use in the treatment of both multiple myeloma (a form of cancer that affects plasma cells) and the complications of leprosy.

«Despite current drugs and use of bone marrow transplantation, multiple myeloma is still incurable, and almost all patients eventually relapse,» says co-principal investigator and multiple myeloma specialist Craig Hofmeister, MD, MPH, assistant professor of medicine and a member of the OSUCCC — James Translational Therapeutics Program.

The find could help scientists develop less - toxic versions of the drug, which has helped combat the cancer multiple myeloma and complications of leprosy.

A new class of drugs for blood cancers such as leukemia and multiple myeloma is showing promise.

Modeling multiple myeloma - bone marrow interactions and response to drugs in a 3D surrogate microenvironment

Recent past honorees include Julian Adams of Infinity Pharmaceuticals, Alfred Goldberg of Harvard Medical School and Kenneth Anderson and Paul Richardson, both of Dana - Farber Cancer Institute, for the development of bortezomib, a drug that has altered the lives of hundreds of thousands of people with multiple myeloma; Alain Carpentier of Hôpital Européen Georges Pompidou in Paris and Robert S. Langer of MIT for innovations in bioengineering; and the work of Harald zur Hausen and Lutz Gissmann of the German Cancer Research Center on human papillomavirus (HPV) and cancer of the cervix, which was recognized by the WAFP prior to their receiving the Nobel Prize.

Previous honorees include David Botstein of Princeton University and Ronald W. Davis and David S. Hogness of Stanford University School of Medicine for their seminal contributions to the concepts and methods of creating a human genetic map, leading to the identification of thousands of disease genes; Julian Adams of Infinity Pharmaceuticals, Alfred Goldberg of Harvard Medical School and Kenneth Anderson and Paul Richardson, both of Dana - Farber Cancer Institute, for the development of bortezomib, a drug that has altered the lives of hundreds of thousands of people with multiple myeloma; Alain Carpentier of Hôpital Européen Georges Pompidou in Paris and Robert S. Langer of MIT for innovations in bioengineering.

The purpose of this study is to identify the most appropriate dose of a new study drug (BAY 1251152) that may treat acute myeloid leukemia or multiple myeloma.

The Multiple Myeloma Research Foundation (MMRF) and its sister research organization, the 22 - member Multiple Myeloma Research Consortium (MMRC), have created a remarkable engine for drug discovery and development in a very short time.

Clinical trials in GVHD, new drugs in leukemia, lymphoma and myeloma.

December 6, 2011 Drug combination highly effective for newly diagnosed myeloma patients, study finds A three - drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical CenDrug combination highly effective for newly diagnosed myeloma patients, study finds A three - drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Cendrug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

While too late to help those whose lives were blighted by the drug during pregnancy, this finding could help rehabilitate thalidomide, which is effective against several serious conditions, including multiple myeloma, a form of cancer.

All in all, the researchers maintain that their results support the use of sorafenib in combination with other drugs in the treatment of multiple myeloma.

Curcumin, the yellow pigment found in turmeric, has the greatest potential for acting as a multipurpose drug in treating and preventing Alzheimer's Disease, a variety of cancers such as skin cancer, pancreatic and colon cancer, osteoarthritis, MGUS and multiple myeloma, and for improving artery function (see also here).